Infectious Disease · Medical Literature
Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study.
Abstract
Seasonal influenza causes considerable morbidity and mortality, with influenza A and B viruses driving most influenza-associated hospitalizations and deaths. Vaccination remains a key influenza prevention strategy; however, current seasonal influenza vaccines based on traditional platforms provide inconsistent protection. Messenger RNA - based vaccines may offer several key advantages over other vaccines, including the flexibility to optimize antigen expression to enhance immunogenicity without the need for adjuvants. mRNA-1010 is an investigational seasonal influenza vaccine candidate that encodes hemagglutinins (HAs) from WHO-recommended influenza strains. In this randomized, phase 2 study, safety, reactogenicity, and immunogenicity of 3 mRNA-1010 vaccine candidate compositions were evaluated in healthy adults aged 18-49 y in the United States (NCT05868382). Eligible participants were randomly assigned to receive a single dose of one of the mRNA-1010 compositions at several dose levels. The primary objective was the safety and reactogenicity of mRNA-1010 vaccine candidate compositions against vaccine-matched strains; secondary and exploratory objectives included humoral and cellular immunogenicity at evaluable timepoints, respectively. Two hundred and seventy participants received study vaccination between May and December 2023. All mRNA-1010 vaccine compositions were well tolerated, with no safety concerns identified; all compositions induced HA-specific humoral and cellular immune responses against all influenza strains evaluated, with the optimized compositions exhibiting higher immune responses against influenza B strains compared with the original mRNA-1010 composition. These results, together with findings from other mRNA-1010 clinical studies, support continued evaluation of mRNA-1010 for enhanced protection against seasonal influenza.Clinical Trials Registration: Clinicaltrials.gov: NCT05868382.
Clinical relevance
Are optimized mRNA-1010 vaccine compositions safe, well-tolerated, and more immunogenic than the original formulation in healthy adults aged 18–49 years? __SNAPSHOT__ {"studyDesign":"Randomized, phase 2 clinical trial","setting":"United States (NCT05868382); institution type not reported","sampleSize":"n=270 total; allocation across 3 compositions and multiple dose levels not reported in abstract","population":"Healthy adults aged 18–49 years with no specific comorbidity exclusion criteria detailed in abstract","intervention":"Single dose of one of 3 optimized mRNA-1010 vaccine candidate compositions at multiple dose levels, each encoding hemagglutinins (HAs) from WHO-recommended influenza strains","comparator":"Comparisons made across the 3 mRNA-1010 compositions (including reference to the original formulation); no licensed vaccine active comparator arm described in the abstract","primaryOutcome":"Safety and reactogenicity of mRNA-1010 vaccine candidate compositions against vaccine-matched influenza strains","followUp":"Immune responses reported to persist through 6 months; full follow-up duration not explicitly stated in abstract","fundingSource":"Industry (Moderna, Inc.; medical writing funded by Moderna)"}
Key findings
All 3 mRNA-1010 compositions were well tolerated, with no safety concerns identified across any arm. All compositions induced HA-specific humoral and polyfunctional CD4+ T-cell immune responses against all influenza strains evaluated, with responses persisting through 6 months. The optimized compositions demonstrated higher immune responses against influenza B strains compared with the original formulation — a notable finding given that prior-generation mRNA-1010 studies showed parity (not superiority) with licensed vaccines for influenza B HAI titers. Secondary and exploratory objectives encompassed humoral and cellular immunogenicity; specific HAI titer magnitudes, geometric mean titer ratios, seroconversion rates, confidence intervals, and p-values are not reported in the abstract. NNT and NNH are not calculable from available data. No vaccine-related serious adverse events are mentioned in the abstract, though the full safety dataset is not described therein.
Practice implications
This phase 2 study establishes that optimized mRNA-1010 compositions are safe and immunogenic in healthy younger adults (18–49 years), and that antigen or sequence optimization can yield meaningfully higher humoral responses against influenza B — a historically problematic component of prior mRNA-1010 iterations. The study does not establish clinical efficacy (i.e., protection against influenza illness), nor does it determine the optimal dose level among those tested. Findings are limited to healthy adults under 50; older adults, immunocompromised individuals, pregnant persons, and those with significant comorbidities were not represented. Because only an abstract is available for detailed review, quantitative immunogenicity comparisons, confidence intervals, and the specific dose levels used cannot be independently appraised. The broader mRNA-1010 clinical program, including a phase 3 trial in adults ≥50 years demonstrating superiority over standard-dose vaccine (rVE 26.6%, 95% CI 16.7–35.4%), provides supporting efficacy context, but that evidence is from a distinct study and formulation. Practice should not change based on this phase 2 study alone; it is best interpreted as a composition-selection and dose-ranging study informing subsequent pivotal trials with the optimized formulation. __LIMITATIONS__ Abstract-only access: quantitative immunogenicity data (HAI titers, GMTs, seroconversion rates, CIs, p-values) are not available for critical appraisal.,No licensed vaccine active comparator arm: inter-composition comparisons do not benchmark against currently approved influenza vaccines, limiting direct clinical contextualization.,Restricted population: healthy adults 18–49 years only; findings cannot be extrapolated to older adults, high-risk groups, or children.,Single-dose design with multiple dose levels and compositions: the optimal dose is not established from the abstract, and multiplicity considerations for secondary/exploratory endpoints are not described.,Immunogenicity as surrogate endpoint: HAI titers and T-cell responses are not validated correlates of protection for all influenza strains in all populations; no clinical efficacy data are reported.,Industry sponsorship (Moderna): introduces potential for reporting bias.,Short enrollment window (May–December 2023): seasonal variation in pre-existing immunity may affect generalizability.,Statistical vs. clinical significance: whether observed improvements in influenza B immunogenicity translate to reduced illness burden is unknown. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In 270 healthy adults aged 18–49 years, all three optimized mRNA-1010 compositions were well tolerated and induced durable HA-specific humoral and CD4+ T-cell responses through 6 months, with improved immunogenicity against influenza B strains relative to the original formulation. This phase 2 composition-optimization study provides a rationale for advancing selected mRNA-1010 formulations into efficacy trials but does not by itself establish clinical protection or guide prescribing decisions. Clinicians should await results from pivotal efficacy trials using the optimized compositions before any practice change.